AKRO:NSD-Akero Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 33.02

Change

0.00 (0.00)%

Market Cap

USD 0.72B

Volume

0.55M

Average Target Price

USD 42.33 (+28.21%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD75.50B 48.39 36.24
REGN Regeneron Pharmaceuticals, Inc

N/A

USD62.07B 30.02 20.75
SGEN Seattle Genetics, Inc

N/A

USD28.53B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

USD24.72B 10.98 9.43
MRNA Moderna, Inc

N/A

USD24.07B N/A N/A
INCY Incyte Corporation

N/A

USD22.68B 47.64 35.20
BMRN BioMarin Pharmaceutical Inc

N/A

USD21.81B 193.21 115.90
GMAB Genmab A/S

N/A

USD21.51B 59.03 6.26
ALNY Alnylam Pharmaceuticals, Inc

N/A

USD17.42B N/A N/A
BGNE BeiGene, Ltd

N/A

USD15.19B N/A N/A

ETFs Containing AKRO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 48.77% 77% C+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 48.77% 77% C+ 87% B+
Trailing 12 Months  
Capital Gain 72.07% 80% B- 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 72.07% 80% B- 89% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 0.75% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.75% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 5.14% N/A N/A N/A N/A
Risk Adjusted Return 14.61% N/A N/A N/A N/A
Market Capitalization 0.72B 69% D+ 66% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 6.42 37% F 21% F
Price / Cash Flow Ratio -20.30 81% B- 88% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -53.49% 64% D 23% F
Return on Invested Capital -115.86% 20% F 7% F
Return on Assets -33.04% 43% F 12% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.96 51% F 43% F
Short Percent 3.97% 61% D- 46% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector